Research Paper Volume 13, Issue 22 pp 24560—24579

Circular RNA CELF1 drives immunosuppression and anti-PD1 therapy resistance in non-small cell lung cancer via the miR-491-5p/EGFR axis

Circ

Figure 8. Circ_CELF1 promotes immunosuppression and resistance to NSCLC immunotherapy. Mouse LLC cells overexpressing circ_CELF1 was subcutaneously injected in mice to establish xenograft mice model, and evaluated immune response. (A) Representative NSCLC cases in which the tissue was analyzed by IHC staining for CD8. (B) A negative correlation between circ_CELF1 and the number of CD8+positive cells was observed in the NSCLC tissues. (C) A negative correlation between EGFR and the number of CD8+positive cells was observed in the NSCLC tissues. (D) A positive correlation between miR-381-3p and the number of CD8-positive cells was observed in the NSCLC tissues. (E) Circ_NC or circ_CELF1 cells were subcutaneously injected into nude mice, and when tumors reached a mean tumor volume of 100 mm3, the mice were treated with an IgG or PD-1 antibody. (F) The data are expressed as the percent of tumors with inhibited growth. (G) Comparison of the overall survival curves for mice with high and low circ_CELF1 expression of xenograft lung tumors that were treated with a mouse antibody against mouse PD-1.